OmniaBio, a CDMO focused on cell and gene therapies, debuted a new manufacturing facility it claims to be the largest of its ...

While radiopharmaceuticals have attracted significant interest in recent years thanks to their cancer-fighting prowess, the ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

Scilex Pharma may soon flee the nest after its parent company Scilex Holding’s board of directors granted permission to ...

The more healthcare professionals (HCPs) know the pharma industry, the more they trust the pharma industry. That is the claim ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella, fears of job cuts and ...

Boston Scientific has launched a docuseries campaign to remove the stigma of male incontinence | Boston Scientific has ...

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...